Back

AstraZeneca Pharma India Signs LoI With Strand Life Sciences

AstraZeneca Pharma India will explore healthcare collaboration in India with Strand Life Sciences, a Reliance Industries subsidiary.

AstraZeneca Pharma India: the AstraZeneca logo over a lab scene with a scientist at a microscope and a DNA strand

Key Takeaways

  • AstraZeneca Pharma India announced on November 17, 2026, that it had signed a letter of intent with Strand Life Sciences.
  • The aim is to explore opportunities to collaborate in healthcare in India.
  • Strand Life Sciences is a genomics research and diagnostics company owned by Reliance Industries.
  • AstraZeneca Pharma India said the LoI is not a related party transaction.
  • The filing did not disclose the scope or any money value of the collaboration.
Table of Contents 6 sections
  1. AstraZeneca Pharma India and Strand LoI at a glance
  2. Who AstraZeneca Pharma India and Strand Life Sciences are
  3. AstraZeneca Pharma India shares the Strand LoI on LinkedIn
  4. How AstraZeneca Pharma India shares moved after the news
  5. Where AstraZeneca Pharma India and Strand stand after the LoI
  6. FAQs

AstraZeneca Pharma India Ltd said on Tuesday, November 17, 2026, that it has signed a letter of intent (LoI) with Strand Life Sciences Pvt Ltd to explore opportunities to collaborate in healthcare in India. Strand Life Sciences is a genomics research and diagnostics company and a subsidiary of Reliance Industries Ltd.

In its filing with the National Stock Exchange, AstraZeneca Pharma India said it and Strand are not related parties, and that signing the LoI does not count as a related party transaction. The filing did not give further details, such as the scope of the planned work or the areas in which the two companies may work together. AstraZeneca Pharma India made the disclosure in a filing with the National Stock Exchange (NSE).

AstraZeneca Pharma India and Strand LoI at a glance

DetailValue
CompaniesAstraZeneca Pharma India Ltd and Strand Life Sciences Pvt Ltd
Type of agreementLetter of intent (LoI)
PurposeTo explore opportunities to collaborate in healthcare in India
Strand's parentReliance Industries Ltd
Related party transactionNo, the companies are not related parties
Disclosed toNational Stock Exchange (NSE)
Announced onNovember 17, 2026

Who AstraZeneca Pharma India and Strand Life Sciences are

AstraZeneca Pharma India is a listed subsidiary of UK-based AstraZeneca Plc. The Indian business was set up in 1979 and is headquartered in Bengaluru, Karnataka. Its key therapy areas include oncology.

Strand Life Sciences is a Bengaluru-based genomics research and diagnostics company. Reliance Industries bought a majority stake in Strand in 2021.

WhenWhat happened
1979AstraZeneca India was set up, with its headquarters in Bengaluru
2021Reliance Industries bought a majority stake in Strand Life Sciences
November 17, 2026AstraZeneca Pharma India announced an LoI with Strand Life Sciences to explore healthcare collaboration in India

AstraZeneca Pharma India shares the Strand LoI on LinkedIn

AstraZeneca Pharma India also shared the news on its LinkedIn page.

The company said the details of the LoI were shared through its LinkedIn handle and its website. It has not announced any money value, timeline or specific projects linked to the LoI.

How AstraZeneca Pharma India shares moved after the news

Shares of AstraZeneca Pharma India rose more than 2% on the NSE on Tuesday after the company announced the LoI with Strand Life Sciences.

Where AstraZeneca Pharma India and Strand stand after the LoI

The LoI lets AstraZeneca Pharma India and Reliance-owned Strand Life Sciences explore working together in healthcare in India, without a related party transaction between them. The company has not shared the scope of the collaboration, and the filing gave no further details beyond the signing of the LoI.

More news

Join Us Add as preferred source
Share

Frequently Asked Questions

What did AstraZeneca Pharma India announce?

AstraZeneca Pharma India announced on November 17, 2026, that it has signed a letter of intent with Strand Life Sciences to explore opportunities to collaborate in healthcare in India.

What is AstraZeneca Pharma India?

AstraZeneca Pharma India is a listed subsidiary of UK-based AstraZeneca Plc, and the Indian business is headquartered in Bengaluru.

What is Strand Life Sciences?

Strand Life Sciences, AstraZeneca Pharma India's new LoI partner, is a Bengaluru-based genomics research and diagnostics company.

Who owns Strand Life Sciences?

Strand Life Sciences, which signed the LoI with AstraZeneca Pharma India, is a subsidiary of Reliance Industries Ltd.

How is the AstraZeneca Pharma India and Strand agreement structured?

AstraZeneca Pharma India signed a letter of intent (LoI) with Strand Life Sciences to explore collaboration, and the filing gave no further details.

How does the LoI affect related party rules for AstraZeneca Pharma India?

AstraZeneca Pharma India said it and Strand Life Sciences are not related parties, so signing the LoI is not a related party transaction.

How much money is involved in the AstraZeneca Pharma India and Strand LoI?

AstraZeneca Pharma India has not disclosed any money value for its LoI with Strand Life Sciences.

How did AstraZeneca Pharma India shares react to the LoI?

AstraZeneca Pharma India shares rose more than 2% on the NSE on November 17, 2026, after the LoI was announced.

When did AstraZeneca Pharma India sign the LoI with Strand?

AstraZeneca Pharma India announced the LoI with Strand Life Sciences on Tuesday, November 17, 2026.

Where did AstraZeneca Pharma India disclose the LoI?

AstraZeneca Pharma India disclosed the LoI with Strand Life Sciences in a filing with the National Stock Exchange.

Where did AstraZeneca Pharma India share the Strand news?

AstraZeneca Pharma India shared the news of the LoI with Strand Life Sciences on its LinkedIn page and its website.

When did Reliance Industries buy into Strand Life Sciences?

Reliance Industries bought a majority stake in Strand Life Sciences, AstraZeneca Pharma India's LoI partner, in 2021.

More in Business